Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Dezember 2022 08:30 ET | Quelle: Blue Water Vaccines Inc.

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022

CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine...
10. November 2022 08:47 ET | Quelle: Blue Water Vaccines Inc.

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in...
21. September 2022 08:00 ET | Quelle: Blue Water Vaccines Inc.

Blue Water Vaccines to Present at World Vaccine Congress Europe 2022

CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
22. August 2022 14:00 ET | Quelle: Blue Water Vaccines Inc.

Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors

CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
13. Mai 2022 17:01 ET | Quelle: Blue Water Vaccines Inc.

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

Closed initial public offering of 2,222,222 shares of common stock at a public offering price of $9.00 per share, with aggregate gross proceeds of approximately $20 millionMultiple vaccine candidate...